

Supplementary Material

Article Title: Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

Authors: Inder Kaul, MD; Amy Claxton, PhD; Sharon Sawchak, RN; Colin Sauder, PhD; Stephen K. Brannan, MD; Edwin Raj, PhD; Shiling Ruan, PhD; George Konis, MD; David Brown, MD; Andrew J. Cutler, MD; and Ronald Marcus, MD

DOI Number: 10.4088/JCP.24m15497

LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE

1. [Table 1](#) Intensity of the Most Common TEAEs
2. [Table 2](#) Subgroup Analysis of TEAEs
3. [Figure 1](#) Daily TEAE Rates Over the 5-Week Treatment Period (Safety Population)
4. [Figure 2](#) Onset and Duration of Commonly Reported TEAEs
5. [Figure 3](#) Mean Supine Blood Pressure

DISCLAIMER

This Supplementary Material has been provided by the authors as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Table 1. Intensity of the Most Common TEAEs^a

TEAE, n (%)	X/T (n=340)			Placebo (n=343)		
	Mild	Moderate	Severe	Mild	Moderate	Severe
Nausea	48 (14.1)	15 (4.4)	0	12 (3.5)	1 (0.3)	0
Constipation	47 (13.8)	11 (3.2)	0	17 (5.0)	4 (1.2)	0
Dyspepsia	38 (11.2)	16 (4.7)	0	15 (4.4)	1 (0.3)	0
Vomiting	31 (9.1)	15 (4.4)	0	4 (1.2)	2 (0.6)	0
Headache	29 (8.5)	8 (2.4)	0	28 (8.2)	8 (2.3)	0
Hypertension	18 (5.3)	11 (3.2)	0	5 (1.5)	1 (0.3)	0
Abdominal pain	14 (4.1)	6 (1.8)	0	9 (2.6)	2 (0.6)	0
Somnolence	10 (2.9)	8 (2.4)	0	12 (3.5)	3 (0.9)	0
Dry mouth	12 (3.5)	5 (1.5)	0	5 (1.5)	0	0
Tachycardia	13 (3.8)	4 (1.2)	0	7 (2.0)	1 (0.3)	0

^aTEAEs occurring in ≥5% of people in the xanomeline/trospium group.


TEAEs=treatment-emergent adverse events; X/T=xanomeline/trospium.

Supplementary Table 2. Subgroup Analysis of TEAEs

TEAEs reported at a difference of >5% between X/T subgroups	Incidence (%)	
	Sex	<i>Female (n=86)</i>
Constipation	30.2	12.6
Nausea	27.9	15.4
Abdominal discomfort	7.0	1.6
Race	<i>Black (n=242)</i>	<i>White (n=92)</i>
Nausea	14.5	28.3
Vomiting	10.7	21.7
Constipation	19.0	10.9
Ethnicity	<i>Hispanic/Latino (n=50)</i>	<i>Not Hispanic/Latino (n=288)</i>
Constipation	26.0	15.6
Headache	16.0	9.7
BMI	<i><30 kg/m² (n=199)</i>	<i>≥30 kg/m² (n=141)</i>
Dyspepsia	12.1	19.9
Vomiting	16.6	9.2
Insomnia	5.5	0.7

BMI=body mass index; TEAEs=treatment-emergent adverse events; X/T, xanomeline/trospium.


Supplementary Figure 1. Daily TEAE Rates Over the 5-Week Treatment Period (Safety Population)




Day 1 is the first day of treatment administration.
AE=adverse event; TEAE=treatment-emergent adverse event; X/T=xanomeline/trospium.

Supplementary Figure 2. Onset and Duration of Commonly Reported TEAEs

A. Onset of TEAE




B. TEAE Duration



Data show mean ± standard deviation.

TEAE=treatment-emergent adverse events; X/T=xanomeline/trospium.

Supplementary Figure 3. Mean Supine Blood Pressure



Systolic and diastolic blood pressure measures recorded at 2 hours post dose (C_{max}).

BL=baseline; C_{max} =maximum concentration; SD=standard deviation; X/T=xanomeline/trospium.